GlassScriptPhysician profile
Van L Jones
NPI 1538332945
$7,357.06
in general payments reported to CMS, 2019-2025
33 companies · $854 in 2025
The $854 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $314 · 2021: $1,258 · 2022: $1,661 · 2023: $1,243 · 2024: $1,309 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,406.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $944.89 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $921.20 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $771.97 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $665.65 | 2021-2025 | Verquvo, Winrevair |
| Boston Scientific Corporation | $606.16 | 2019-2025 | Watchman Access System, Farapulse, Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $504.58 | 2019-2022 | |
| Pfizer INC. | $344.74 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $321.50 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $279.95 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $264.77 | 2021-2025 | |
| Esperion Therapeutics, INC. | $222.80 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $219.10 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $206.17 | 2019-2025 | Camzyos, Eliquis |
| Philips North America LLC | $174.29 | 2020-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.19 | 2021-2025 | Lifevest |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $118.12 | 2022-2024 | Optimizer, Optimizer |
| Lexicon Pharmaceuticals, INC. | $100.82 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $91.93 | 2019-2023 | Evkeeza |
| Kestra Medical Technology Services, INC. | $85.36 | 2025 | Assure Wcd |
| Amarin Pharma, INC. | $55.24 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $47.62 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $44.15 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $39.16 | 2025 | Attruby |
| Tactile Systems Technology INC | $33.95 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Amryt Pharma Holdings LTD | $28.45 | 2020-2021 | |
| Abbott Laboratories | $24.99 | 2021 | |
| Glaxosmithkline, LLC. | $21.11 | 2025 | Trelegy Ellipta |
| Kiniksa Pharmaceuticals, LTD. | $19.69 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $18.29 | 2023 | Inspire |
| Actelion Pharmaceuticals US, INC. | $16.08 | 2025 | Opsumit, Uptravi |
| Scpharmaceuticals INC. | $15.56 | 2024 | |
| Gilead Sciences, INC. | $11.99 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.